SIGA Technologies, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report; standalone fourth-quarter results are not clearly provided in the filing text. Amounts below are in U.S. dollars.
Business context
SIGA is a commercial-stage pharmaceutical company whose business is centered on TPOXX (tecovirimat), an FDA-approved oral treatment for smallpox. U.S. oral sales are limited to government stockpiling and use. Most revenue is generated under U.S. government contracts; international sales are promoted through Meridian. SIGA relies on contract manufacturers rather than operating its own manufacturing infrastructure.
Financial results and liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Total revenue | $133.7 million | $125.0 million | Up 7.0% |
| Product sales and supportive services | $126.8 million | $115.5 million | Up 9.8% |
| Research and development revenue | $6.9 million | $9.5 million | Down 27.6% |
| Operating income | $89.1 million | $84.5 million | Up 5.4% |
| Net income | $69.5 million | $56.3 million | Up 23.3% |
| Diluted earnings per share | $0.91 | $0.71 | Up $0.20 |
| Net cash from operating activities | $11.5 million | $71.5 million | Down $60.0 million |
| Cash and cash equivalents at year-end | $103.1 million | $117.9 million | Down $14.8 million |
Operating margin was approximately 66.7% (67.6% in 2020); net margin was approximately 52.0% (45.1% in 2020). Cost of sales and supportive services was $16.6 million, including a $0.6 million net inventory-related loss. The filing does not present a single headline gross-margin figure; product sales and supportive services less those costs imply an approximate 86.9% margin.
Operating cash flow fell primarily because year-end receivables rose to $83.7 million from $3.3 million. This included $79.7 million of U.S. government product delivered and invoiced in December, paid in January 2022. Cash flow also reflected manufacturing inventory and ordinary operating needs. The company repurchased approximately 3.8 million shares for $26.0 million during 2021.
There was no term-loan debt at year-end; the loan had been repaid in March 2020. Current assets were $208.8 million and current liabilities $30.5 million, for a current ratio of approximately 6.8. Total liabilities were $40.4 million, including a $6.5 million warrant liability and lease obligations. The company reported $20.1 million in outstanding manufacturing purchase commitments.
Material changes and commercial developments
- U.S. government TPOXX sales were $112.5 million in 2021, roughly flat with $112.6 million in 2020. International product revenue increased to $12.7 million from $2.3 million, including deliveries to Canadian government customers.
- BARDA exercised an option in September 2021 for approximately $112.6 million of oral TPOXX. Of the 19C BARDA Contract’s approximately $602.5 million potential value, $239.7 million related to exercised options and up to $311.1 million remained unexercised at year-end.
- Health Canada approved oral tecovirimat in December 2021. The European Medicines Agency approval, announced January 10, 2022, covered smallpox, monkeypox, cowpox and certain vaccinia complications. These are post-year-end developments.
- SIGA filed an FDA application for IV TPOXX in April 2021 and was targeting completion of FDA review in the first half of 2022; approval was not assured.
- Operating expenses rose to $44.6 million from $40.5 million, driven in part by international promotion fees and higher insurance, business development and consulting costs. R&D expense decreased to $9.9 million from $10.9 million.
Outlook, risks and unusual items
- The filing gives no quantified company revenue or earnings guidance. Management estimated that approximately 940,000 courses would need to be delivered to the U.S. government during 2022–2024 to maintain unexpired stockpile levels; this is an estimate, not a committed order.
- Revenue prospects are highly dependent on government procurement. BARDA may exercise or decline remaining options in its sole discretion, and government contracts can be modified or terminated. More than 90% of the remaining value of the 19C contract was option-based.
- International growth depends substantially on Meridian’s promotion efforts and on government decisions. A proposed January 2022 PHAC amendment would increase potential contract procurement to $38 million, including firm cumulative purchases of approximately $23 million by March 31, 2023; the remaining amount was subject to options.
- SIGA depends on third-party manufacturers and suppliers. COVID-19-related supply-chain, research, contract-administration and international-award delays remain risks, although management said it had not identified a material liquidity impact from the pandemic at the filing date.
- IV TPOXX sales under current contract terms would have an estimated gross margin below 40% if the relevant final-product options were exercised. The company estimated international oral TPOXX contribution margins of approximately 65%–80%, before expenses not directly related to manufacturing or Meridian activities.
- Unusual 2020 comparisons include a $5.0 million loan-extinguishment loss, $3.0 million of interest expense and a $3.5 million warrant fair-value loss; these were absent or materially different in 2021. In 2021, warrant remeasurement produced a $0.1 million gain.
- The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting. The audit highlighted revenue recognition estimates for costs to complete R&D performance obligations as a critical audit matter.
Important facts for investors to verify
- Whether and when BARDA exercises the $311.1 million of remaining 19C contract options, and the economics of any resulting deliveries.
- Collection and working-capital timing for the large year-end receivable, including confirmation of the disclosed January 2022 payment.
- FDA disposition and any restrictions or required studies for IV TPOXX, alongside actual commercialization and delivery timelines.
- Whether Canadian and other international procurement commitments become firm orders and translate into revenue and cash receipts.
- Manufacturing capacity, supply continuity, inventory quality and the effect of fixed-price contract costs on margins.